Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $28.00 Consensus Target Price from Analysts

Bicara Therapeutics Inc. (NASDAQ:BCAX) has been given a consensus recommendation of “Moderate Buy” by the eight research firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and five have issued a buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $28.0013.

BCAX has been the topic of a number of analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Tuesday, October 14th. Mizuho upgraded shares of Bicara Therapeutics to a “hold” rating in a report on Thursday, December 18th. Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $8.00 to $11.00 and gave the company an “equal weight” rating in a research note on Tuesday, November 11th. BTIG Research started coverage on shares of Bicara Therapeutics in a research report on Thursday. They set a “buy” rating and a $28.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Bicara Therapeutics in a report on Monday, November 10th.

Insider Activity at Bicara Therapeutics

In other Bicara Therapeutics news, COO Ryan Cohlhepp sold 12,500 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $18.68, for a total transaction of $233,500.00. Following the completion of the transaction, the chief operating officer owned 189,141 shares in the company, valued at $3,533,153.88. This trade represents a 6.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Claire Mazumdar sold 41,163 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The shares were sold at an average price of $18.86, for a total transaction of $776,334.18. Following the completion of the sale, the chief executive officer directly owned 309,892 shares in the company, valued at approximately $5,844,563.12. This trade represents a 11.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 127,297 shares of company stock valued at $2,371,916 over the last quarter. 15.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Bicara Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Legal & General Group Plc boosted its holdings in shares of Bicara Therapeutics by 64.1% in the second quarter. Legal & General Group Plc now owns 3,156 shares of the company’s stock worth $29,000 after acquiring an additional 1,233 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in Bicara Therapeutics by 73.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,493 shares of the company’s stock worth $32,000 after purchasing an additional 1,474 shares in the last quarter. Larson Financial Group LLC boosted its stake in Bicara Therapeutics by 1,015.5% in the 3rd quarter. Larson Financial Group LLC now owns 3,949 shares of the company’s stock worth $62,000 after purchasing an additional 3,595 shares during the period. Tower Research Capital LLC TRC grew its holdings in Bicara Therapeutics by 419.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,788 shares of the company’s stock valued at $44,000 after buying an additional 3,866 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey grew its holdings in Bicara Therapeutics by 119.6% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 8,109 shares of the company’s stock valued at $75,000 after buying an additional 4,417 shares in the last quarter.

Bicara Therapeutics Stock Performance

Shares of BCAX opened at $17.95 on Monday. The firm has a market capitalization of $983.30 million, a P/E ratio of -8.01 and a beta of -0.79. Bicara Therapeutics has a 52 week low of $7.80 and a 52 week high of $19.71. The stock has a 50 day moving average price of $16.96 and a two-hundred day moving average price of $14.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its earnings results on Monday, November 10th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.12). On average, equities analysts forecast that Bicara Therapeutics will post -2.59 earnings per share for the current year.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.